RE: Related industry news....LABS CEO basically put it out there in between the lines....looking for "strategic fit" in the last CC. Pfizer does not have extraction, isolation, as well as those highly sought after "derivative products" expertise and to develop that would take years. LABS on the other hand does not have the financial resources to fuel a hyper growth phase leading to the estimated $25 billion market in cannabinoid API sales forecasted by 2025. There is the strategic fit and imho, well over $25 billion when combining cannabinoid API sales and novel cannabinoid based drugs.
No different than finding out that LABS and VIVO were in talks back in July 2022 and letting the news out in December of 2022.
All of sudden, the CEO of LABS is referring to Pfizer (yet to be announced) as their "partner" and not just a customer.
A deal exists involving a partnership, in the legal business sense.
Mr. Pidduck, a lot of heart burn....don't forget that and it's always best served stone cold.